Merck settlement includes ACCME policies agreement

Share this article:
Merck's settlement of Vioxx litigation with 29 states included agreements to abide by ACCME policies regarding disclosure of relationships between speakers and companies and not to fund programs featuring speakers who have spoken at a Merck-sponsored promotional event on a drug in the relevant class within the last 12 months. The settlement commits Merck to these conditions for nine years. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.